TITLE

Eprosartan: A Review of its Use in the Management of Hypertension

AUTHOR(S)
Plosker, G.L.; Foster, R.H.
PUB. DATE
July 2000
SOURCE
Drugs;Jul2000, Vol. 60 Issue 1, p177
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Eprosartan is a potent and selective angiotensin II subtype 1 receptor antagonist. Results of large (n > 100) randomised double-blind studies in patients with mild, moderate or severe hypertension demonstrated that the antihypertensive efficacy of eprosartan (usually 400 to 800 mg/day as a single daily dose or in 2 divided doses) is significantly greater than that of placebo and at least as good as that of enalapril. In placebo-controlled trials, eprosartan achieved mean reductions from baseline in trough sitting systolic blood pressure of 6.3 to 15mm Hg and in diastolic blood pressure of 4.1 to 9.7mm Hg. Response rates associated with once daily administration of eprosartan 400 to 800mg were approximately double those with placebo. Overall, eprosartan was well tolerated with a similar tolerability profile to that of placebo. In comparative trials, in which the incidence of persistent dry cough was evaluated as the primary end-point, enalapril was several-fold more likely to induce this adverse event than eprosartan (the difference being statistically significant regardless of study population and definition of cough). In conclusion, the angiotensin II receptor antagonist eprosartan is a well tolerated and effective antihypertensive agent that is administered once or twice daily without regard to meals. Eprosartan has a low potential for serious adverse events, and the drug has not been associated with clinically significant drug interactions. Unlike ACE inhibitors such as enalapril, eprosartan does not have a high propensity to cause persistent nonproductive cough. Thus, eprosartan represents a useful therapeutic option in the management of patients with hypertension.
ACCESSION #
9592991

 

Related Articles

  • Telmisartan: A Viewpoint by Wilbert S. Aronow. Aronow, W.S. // Drugs;Dec1998, Vol. 56 Issue 6, p1045 

    Comments on a study on the use of the nonpeptide angiotensin II receptor antagonist telmisartan in the management of hypertension. Details on the dosage and administration of telmisartan; Information on the effectiveness of telmisartan.

  • Angiotensin II receptor antagonists in hypertension. Burnier, Michel; Brunner, Hans R. // Kidney International Supplement;Dec1998, Issue 68, pS-107 

    Examines the efficacy of angiotensin II receptor antagonist for the treatment of hypertension. Route of administration; Therapeutic dosage of angiotensin; Sensitivity of angiotensin.

  • Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information. Powers, Benjamin; Coeytaux, Remy; Dolor, Rowena; Hasselblad, Vic; Patel, Uptal; Yancy, William; Gray, Rebecca; Irvine, R.; Kendrick, Amy; Sanders, Gillian // JGIM: Journal of General Internal Medicine;Jun2012, Vol. 27 Issue 6, p716 

    OBJECTIVES: A 2007 systematic review compared angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in patients with hypertension. Direct renin inhibitors (DRIs) have since been introduced, and significant new research has been published. We sought to update...

  • Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Baumhäkel, M; Schlimmer, N; Böhm, M // International Journal of Impotence Research;Sep/Oct2008, Vol. 20 Issue 5, p493 

    Pathogenesis of erectile dysfunction (ED) is related to endothelial dysfunction and therefore associated with cardiovascular risk factors. Patients with a combination of risk factors, as in metabolic syndrome, are thus likely to have an increased risk of developing endothelial and ED. The...

  • Efficacy and Tolerability of Irbesartan, an Angiotensin II Receptor Antagonist, in Primary Hypertension: A Double-Blind, Placebo-Controlled, Dose-Titration Study. Guthrie, R.; Saini, R.; Herman, T.; Pleskow, W.; Sprecher, D.; Collins, G. // Clinical Drug Investigation;1998, Vol. 15 Issue 3, p217 

    This study compared the efficacy and tolerability of two dose-titrated regimens of irbesartan, an angiotensin II receptor antagonist selective for the AT subtype, vs placebo in hypertensive patients when titrated to clinical response. Patients with seated diastolic blood pressure (SeDBP) 95 to...

  • Influence of losartan and atenolol on memory function in very elderly hypertensive patients. Fogari, R.; Mugellini, A.; Zoppi, A.; Derosa, G.; Pasotti, C.; Fogari, E.; Preti, P. // Journal of Human Hypertension;Nov2003, Vol. 17 Issue 11, p781 

    The aim of this study was to compare the effect of the beta-adrenergic blocker atenolol and the Angiotensin II type 1 (AT1) receptor antagonist losartan on cognitive function in very elderly hypertensive patients. A total of 120 mild to moderate essential hypertensive (DBP >90 and <105?mmHg)...

  • Chapter 2: CARDIOVASCULAR DISEASE: 2F: Hypertension.  // Monthly Prescribing Reference;Aug2014, Vol. 30 Issue 8, p31 

    The article offers brief information on several drugs for hypertension including the Accupril from the firm Pfizer, the Atacand HCT from the firm AstraZeneca, the Avalide from the firm Sanofi Aventis.

  • Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. Israili, Z H // Journal of Human Hypertension;Apr2000 Supplement, Vol. 14 Issue 4, pS73 

    Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihy-pertensive agents. Recent clinical trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic...

  • Angiotensin II receptor antagonists in arterial hypertension. Hernandez-Hernandez, R; Velasco, M; Armas-Hernandez, M J; Armas-Padilla, M C // Journal of Human Hypertension;Apr2000 Supplement, Vol. 14 Issue 4, pS69 

    Angiotensin II receptor antagonists (AT-1) represent a new group of orally active anti-hypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and anti-diuretic hormone with production of thirst, and promote growth of vascular and...

  • AT [sub1] receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Welch, William J.; Wilcox, Christopher S. // Kidney International;Apr2001, Vol. 59 Issue 4, p1257 

    AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. The tubuloglomerular feed- back (TGF) responses of the spontaneously hypertensive rat (SHR) are under exaggerated regulation by angiotensin II (Ang II) type 1 receptors (AT1-R). Since AT1-Rs enhance...

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics